{"pmid":32474033,"title":"Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis.","text":["Markers of liver injury and clinical outcomes in COVID-19 patients: A systematic review and meta-analysis.","J Infect","Kunutsor, Setor K","Laukkanen, Jari A","32474033"],"journal":"J Infect","authors":["Kunutsor, Setor K","Laukkanen, Jari A"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474033","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.jinf.2020.05.045","topics":["Treatment","Diagnosis"],"weight":1,"_version_":1668341932697321474,"score":9.490897,"similar":[{"pmid":32445489,"title":"COVID-19 and Liver Dysfunction: a systematic review and meta-analysis of retrospective studies.","text":["COVID-19 and Liver Dysfunction: a systematic review and meta-analysis of retrospective studies.","BACKGROUND: Recently, Coronavirus Disease 2019 (COVID-19) pandemic is the most significant global health crisis. In this study, we conducted a meta-analysis to find the association between liver injuries and the severity of COVID-19 disease. METHODS: Online databases, including PubMed, Web of Science, Scopus, and Science direct, were searched to detect relevant publications up to April 16, 2020. Depending on the heterogeneity between studies, a fixed- or random-effects model was applied to pool data. Publication bias Egger's test was also performed. RESULTS: Meta-analysis of 20 retrospective studies (3428 patients), identified that patients with a severe manifestation of COVID-19 exhibited significantly higher levels of alanine aminotransferase, aspartate aminotransferase, and bilirubin values with prolonged prothrombin time. Furthermore, lower albumin level was associated with a severe presentation of COVID-19. CONCLUSION: Liver dysfunction was associated with a severe outcome of COVID-19 disease. Close monitoring of the occurrence of liver dysfunction is beneficial in early warning of unfavorable outcomes. This article is protected by copyright. All rights reserved.","J Med Virol","Youssef, Mohanad","Hussein, Mohammad","Attia, Abdallah S","Elshazli, Rami","Omar, Mahmoud","Zora, Ghassan","Farhoud, Ashraf","Elnahla, Ahmad","Shihabi, Areej","Toraih, Eman","Fawzy, Manal","Kandil, Emad","32445489"],"abstract":["BACKGROUND: Recently, Coronavirus Disease 2019 (COVID-19) pandemic is the most significant global health crisis. In this study, we conducted a meta-analysis to find the association between liver injuries and the severity of COVID-19 disease. METHODS: Online databases, including PubMed, Web of Science, Scopus, and Science direct, were searched to detect relevant publications up to April 16, 2020. Depending on the heterogeneity between studies, a fixed- or random-effects model was applied to pool data. Publication bias Egger's test was also performed. RESULTS: Meta-analysis of 20 retrospective studies (3428 patients), identified that patients with a severe manifestation of COVID-19 exhibited significantly higher levels of alanine aminotransferase, aspartate aminotransferase, and bilirubin values with prolonged prothrombin time. Furthermore, lower albumin level was associated with a severe presentation of COVID-19. CONCLUSION: Liver dysfunction was associated with a severe outcome of COVID-19 disease. Close monitoring of the occurrence of liver dysfunction is beneficial in early warning of unfavorable outcomes. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Youssef, Mohanad","Hussein, Mohammad","Attia, Abdallah S","Elshazli, Rami","Omar, Mahmoud","Zora, Ghassan","Farhoud, Ashraf","Elnahla, Ahmad","Shihabi, Areej","Toraih, Eman","Fawzy, Manal","Kandil, Emad"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445489","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/jmv.26055","keywords":["covid-19","sars-cov-2","liver function","meta-analysis","outcome"],"locations":["Scopus"],"e_drugs":["Bilirubin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667600475863646208,"score":58.980484},{"pmid":32418852,"title":"The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.","text":["The liver injury and gastrointestinal symptoms in patients with Coronavirus Disease 19: A systematic review and meta-analysis.","BACKGROUNDS: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19. METHODS: A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19. RESULTS: A total of 21 studies with 3024 patients were included. Up to 53% patients had liver dysfunctions and the degree of liver damage was associated the severity of the disease. The prevalence of diarrhoea, nausea/vomiting or abdominal pain in patients with COVID-19 were 9.1%, 5.2% and 3.5%, respectively. No significant was found in the prevalence of diarrhoea (OR, 1.24; 95%CI, 0.90 to 1.72; I(2)=0%, P=0.19) and nausea/vomiting (OR, 1.24; 95%CI, 0.57 to 2.69; I(2)=61%, P=0.58) between severe and non-severe patients. In addition, diarrhoea (OR, 1.22; 95%CI, 0.50 to 2.98; I(2)=0%, P=0.66) and nausea/vomiting (OR, 1.09; 95%CI, 0.46 to 2.62; I(2)=0%, P=0.84) were not associated with the prognosis of COVID-19 patients. CONCLUSIONS: The incidences of GIS in patients with COVID-19 is relatively low and are not associated with the COVID-19 progression. Gastroenterologists should pay more attention to the liver injury induced by SARS-CoV-2 during the course of infection.","Clin Res Hepatol Gastroenterol","Wang, Haizhou","Qiu, Peishan","Liu, Jing","Wang, Fan","Zhao, Qiu","32418852"],"abstract":["BACKGROUNDS: Since December 2019, novel coronavirus (SARS-CoV-2)-infected pneumonia (COVID-19) occurred in Wuhan, and rapidly spread throughout China. Our study aimed to evaluate the association of liver injury and gastrointestinal symptoms (GIS) with the progression of COVID-19. METHODS: A comprehensive search was performed on the PubMed to identify eligible studies that summarized the liver injury and GIS in COVID-19. RESULTS: A total of 21 studies with 3024 patients were included. Up to 53% patients had liver dysfunctions and the degree of liver damage was associated the severity of the disease. The prevalence of diarrhoea, nausea/vomiting or abdominal pain in patients with COVID-19 were 9.1%, 5.2% and 3.5%, respectively. No significant was found in the prevalence of diarrhoea (OR, 1.24; 95%CI, 0.90 to 1.72; I(2)=0%, P=0.19) and nausea/vomiting (OR, 1.24; 95%CI, 0.57 to 2.69; I(2)=61%, P=0.58) between severe and non-severe patients. In addition, diarrhoea (OR, 1.22; 95%CI, 0.50 to 2.98; I(2)=0%, P=0.66) and nausea/vomiting (OR, 1.09; 95%CI, 0.46 to 2.62; I(2)=0%, P=0.84) were not associated with the prognosis of COVID-19 patients. CONCLUSIONS: The incidences of GIS in patients with COVID-19 is relatively low and are not associated with the COVID-19 progression. Gastroenterologists should pay more attention to the liver injury induced by SARS-CoV-2 during the course of infection."],"journal":"Clin Res Hepatol Gastroenterol","authors":["Wang, Haizhou","Qiu, Peishan","Liu, Jing","Wang, Fan","Zhao, Qiu"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418852","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.clinre.2020.04.012","keywords":["covid-19","diarrhoea","gastrointestinal symptoms","liver injury","sars-cov-2"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1667254896696492032,"score":57.968105},{"pmid":32359177,"title":"Longitudinal association between markers of liver injury and mortality in COVID-19 in China.","text":["Longitudinal association between markers of liver injury and mortality in COVID-19 in China.","Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization.","Hepatology","Lei, Fang","Liu, Ye-Mao","Zhou, Feng","Qin, Juan-Juan","Zhang, Peng","Zhu, Lihua","Zhang, Xiao-Jing","Cai, Jingjing","Lin, Lijin","Ouyang, Shan","Wang, Xiaoming","Yang, Chengzhang","Cheng, Xu","Liu, Weifang","Li, Haomiao","Xie, Jing","Wu, Bin","Luo, Huiming","Xiao, Fei","Chen, Jing","Tao, Liang","Cheng, Gang","She, Zhi-Gang","Zhou, Jianghua","Wang, Haitao","Lin, Jun","Luo, Pengcheng","Fu, Shouzhi","Zhou, Jihui","Ye, Ping","Xiao, Bing","Mao, Weiming","Liu, Liming","Yan, Youqin","Liu, Ling","Chen, Guohua","Li, Hongliang","Huang, Xiaodong","Zhang, Bing-Hong","Yuan, Yufeng","32359177"],"abstract":["Coronavirus disease 2019 (COVID-19) is a new infectious disease. To reveal the hepatic injury related to this disease and its clinical significance, we conducted a multicenter retrospective cohort study that included 5,771 adult patients with COVID-19 pneumonia in Hubei Province. We reported the distributional and temporal patterns of liver injury indicators in these patients and determined their associated factors and death risk. Longitudinal liver function tests were retrospectively analyzed and correlated with the risk factors and death. Liver injury dynamic patterns differed in alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bilirubin (TBIL). AST elevated first, followed by ALT, in severe patients. ALP modestly increased during hospitalization and largely remained in the normal range. The fluctuation in TBIL levels was mild in the non-severe and the severe group. AST abnormality was associated with the highest mortality risk compared to other indicators of liver injury during hospitalization. Common factors associated with elevated liver injury indicators were lymphocyte count decrease, neutrophil count increase, and male gender. CONCLUSION: The dynamic patterns of liver injury indicators and their potential risk factors may provide an important explanation for the COVID-19-associated liver injury. Because elevated liver injury indicators, particularly AST, are strongly associated with the mortality risk, our study indicates that these parameters should be monitored during hospitalization."],"journal":"Hepatology","authors":["Lei, Fang","Liu, Ye-Mao","Zhou, Feng","Qin, Juan-Juan","Zhang, Peng","Zhu, Lihua","Zhang, Xiao-Jing","Cai, Jingjing","Lin, Lijin","Ouyang, Shan","Wang, Xiaoming","Yang, Chengzhang","Cheng, Xu","Liu, Weifang","Li, Haomiao","Xie, Jing","Wu, Bin","Luo, Huiming","Xiao, Fei","Chen, Jing","Tao, Liang","Cheng, Gang","She, Zhi-Gang","Zhou, Jianghua","Wang, Haitao","Lin, Jun","Luo, Pengcheng","Fu, Shouzhi","Zhou, Jihui","Ye, Ping","Xiao, Bing","Mao, Weiming","Liu, Liming","Yan, Youqin","Liu, Ling","Chen, Guohua","Li, Hongliang","Huang, Xiaodong","Zhang, Bing-Hong","Yuan, Yufeng"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359177","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1002/hep.31301","locations":["Hubei","neutrophil","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Bilirubin"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1666138495344705537,"score":57.88931},{"pmid":32429038,"title":"Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.","text":["Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis.","The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients.","Trop Med Infect Dis","Oyelade, Tope","Alqahtani, Jaber","Canciani, Gabriele","32429038"],"abstract":["The mortality and severity in COVID-19 is increased in patients with comorbidities. The aim of this study was to evaluate the severity and mortality in COVID-19 patients with underlying kidney and liver diseases. We retrieved data on the clinical features and primary composite end point of COVID-19 patients from Medline and Embase which had been released from inception by the April 16, 2020. The data on two comorbidities, liver diseases and chronic kidney disease, were pooled and statistically analysed to explain the associated severity and mortality rate. One hundred and forty-two abstracts were screened, and 41 full articles were then read. In total, 22 studies including 5595 COVID-19 patients were included in this study with case fatality rate of 16%. The prevalence of liver diseases and chronic kidney disease (CKD) were 3% (95% CI; 2-3%) and 1% (95% CI; 1-2%), respectively. In patients with COVID-19 and underlying liver diseases, 57.33% (43/75) of cases were severe, with 17.65% mortality, while in CKD patients, 83.93% (47/56) of cases were severe and 53.33% (8/15) mortality was reported. This study found an increased risk of severity and mortality in COVID-19 patients with liver diseases or CKD. This will lead to better clinical management and inform the process of implementing more stringent preventative measures for this group of patients."],"journal":"Trop Med Infect Dis","authors":["Oyelade, Tope","Alqahtani, Jaber","Canciani, Gabriele"],"date":"2020-05-21T11:00:00Z","year":2020,"_id":"32429038","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/tropicalmed5020080","keywords":["covid-19","sars-cov-2","alcohol-related liver disease","chronic kidney disease","cirrhosis","hepatitis b and c","necrosis","nonalcoholic steatohepatitis"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1667342288360046593,"score":56.994278},{"pmid":32425643,"pmcid":"PMC7233226","title":"Association of inflammatory markers with the severity of COVID-19: a meta-analysis.","text":["Association of inflammatory markers with the severity of COVID-19: a meta-analysis.","Objectives: Studies reported associations of inflammatory markers with the severity of COVID-19, but conclusions were inconsistent. We aimed to provide an overview of the association of inflammatory markers with severity of COVID-19. Methods: We searched PubMed, Embase, Cochrane Library, Wanfang and China National Knowledge Infrastructure (CNKI) database until March 20, 2020. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models. Results: A total of 16 studies comprising of 3962 patients with COVID-19 were included in our analysis. Random-effect results demonstrated that patients with COVID-19 in nonsevere group had lower levels for CRP (WMD = -41.78 mg/l, 95% CI = [-52.43, -31.13], P < 0.001), PCT (WMD = -0.13 ng/ml, 95% CI = [-0.20, -0.05], P < 0.001), IL-6 (WMD = -21.32 ng/l, 95% CI = [-28.34, -14.31], P < 0.001), ESR (WMD = -8 mm/h, 95% CI = [-14, -2], P = 0.005), SAA (WMD = -43.35 mug/ml, 95% CI = [-80.85, -5.85], P = 0.020) and serum ferritin (WMD = -398.80 mg/l, 95% CI = [-625.89, -171.71], P < 0.001), compared with those in severe group. Moreover, survivors had a lower level for IL-6 than non-survivors (WMD = -4.80 ng/ml, 95% CI = [-5.87, -3.73], P < 0.001). These results were consistent through sensitivity analysis and publication bias assessment. Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19. Measurement of inflammatory markers might assist clinicians to monitor and evaluate the severity and prognosis of COVID-19.","Int J Infect Dis","Zeng, Furong","Huang, Yuzhao","Guo, Ying","Yin, Mingzhu","Chen, Xiang","Xiao, Liang","Deng, Guangtong","32425643"],"abstract":["Objectives: Studies reported associations of inflammatory markers with the severity of COVID-19, but conclusions were inconsistent. We aimed to provide an overview of the association of inflammatory markers with severity of COVID-19. Methods: We searched PubMed, Embase, Cochrane Library, Wanfang and China National Knowledge Infrastructure (CNKI) database until March 20, 2020. Weighted mean difference (WMD) and 95% confidence intervals (CIs) were pooled using random or fixed-effects models. Results: A total of 16 studies comprising of 3962 patients with COVID-19 were included in our analysis. Random-effect results demonstrated that patients with COVID-19 in nonsevere group had lower levels for CRP (WMD = -41.78 mg/l, 95% CI = [-52.43, -31.13], P < 0.001), PCT (WMD = -0.13 ng/ml, 95% CI = [-0.20, -0.05], P < 0.001), IL-6 (WMD = -21.32 ng/l, 95% CI = [-28.34, -14.31], P < 0.001), ESR (WMD = -8 mm/h, 95% CI = [-14, -2], P = 0.005), SAA (WMD = -43.35 mug/ml, 95% CI = [-80.85, -5.85], P = 0.020) and serum ferritin (WMD = -398.80 mg/l, 95% CI = [-625.89, -171.71], P < 0.001), compared with those in severe group. Moreover, survivors had a lower level for IL-6 than non-survivors (WMD = -4.80 ng/ml, 95% CI = [-5.87, -3.73], P < 0.001). These results were consistent through sensitivity analysis and publication bias assessment. Conclusions: The meta-analysis highlights the association of inflammatory markers with the severity of COVID-19. Measurement of inflammatory markers might assist clinicians to monitor and evaluate the severity and prognosis of COVID-19."],"journal":"Int J Infect Dis","authors":["Zeng, Furong","Huang, Yuzhao","Guo, Ying","Yin, Mingzhu","Chen, Xiang","Xiao, Liang","Deng, Guangtong"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425643","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.ijid.2020.05.055","keywords":["covid-19","sars-cov-2","inflammatory markers","meta-analysis","severity"],"locations":["Wanfang","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Diagnosis","Treatment"],"weight":1,"_version_":1667252838029328384,"score":56.5121}]}